Market Overview

Once Again, Baird Predicts End To Tandem's 'Fantastic' Run

Share:
Once Again, Baird Predicts End To Tandem's 'Fantastic' Run
Related
33 Stocks Moving In Wednesday's Pre-Market Session
The Daily Biotech Pulse: AbbVie's Leukemia Drug Trial Meets Endpoint, Denali Strikes Collaboration Deal

Without pause, Tandem Diabetes Care Inc (NASDAQ: TNDM) has surged 1,915 percent year-to-date. One sell-side analyst said Friday that the medical device manufacturer's valuation has peaked. 

The Rating

Baird Equity Research analyst Jeff Johnson downgraded Tandem from Outperform to Neutral and raised the price target from $42 to $47.

The Thesis

Tandem awaits a number of near-term catalysts that could bolster its valuation, Johnson said in the Friday downgrade note. (See his track record here.) 

The ramp of Basal-IQ, mid-2019 launch of Control-IQ, late 2018 penetration of the international market and possible resumption of coverage under UnitedHealth Group Inc (NYSE: UNH) could help sustain a relatively high stock price, the analyst said. 

As such, Baird isn't too concerned with Tandem’s fundamentals.

“For the vast majority of that run, we've been fully on board, as we continue to believe TNDM is well-positioned to continue gaining share in the rapidly expanding $3-billion worldwide insulin pump/AID market." 

Even considering the possible growth opportunities, the analyst said Tandem trades between 45 and 55 times the 2021 forecast for earnings before interest, tax, depreciation and amortization.

“Even in this crazy medtech market, we believe that feels aggressive, especially as it also represents a sizable (15-50 percent) premium to the 2021 EBITDA multiple at which we estimate diabetes peers PODD and DXCM currently trade,” Johnson said, referencing Insulet Corporation (NASDAQ: PODD) and DexCom, Inc. (NASDAQ: DXCM).

It’s worth noting that Baird has been wrong before.

“Over the course of TNDM's fantastic run this year, we've thought many times this stock might be due for a breather, only to be proven wrong each time,” the analyst said. “Given that, we fully acknowledge the potential near-term folly of our trying to make a valuation call on this name today.”

Price Action

At the time of publication, Tandem shares were down 7.48 percent at $47.34. 

Related Links:

'A New Revolution Of Medicine': Senseonics Brings Automation To Diabetes Care

Piper Jaffray: Tandem Diabetes Is Entering A 'Goldilocks Period'

Photo courtesy of Tandem Diabetes. 

Latest Ratings for TNDM

DateFirmActionFromTo
Sep 2018Craig-HallumInitiates Coverage OnBuy
Sep 2018BairdDowngradesOutperformNeutral
Aug 2018BerenbergInitiates Coverage OnBuy

View More Analyst Ratings for TNDM
View the Latest Analyst Ratings

Posted-In: Baird Equity Research Jeff JohnsonAnalyst Color Downgrades Health Care Price Target Analyst Ratings General Best of Benzinga

 

Related Articles (DXCM + PODD)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
BBCIBCUpgrades0.0
BKNGWells FargoUpgrades0.0
DARJP MorganUpgrades25.0
EEXBarclaysDowngrades12.0
HPCredit SuisseUpgrades65.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Bet On Breakouts With This New ETF

Mid-Morning Market Update: Markets Edge Higher; Dave & Buster's Tops Q2 Views